Organization | Grupo Español Multidisciplinar de Melanoma

Grupo Español Multidisciplinar de Melanoma Report issue

Academic/Hospital Phase 2

Founded: Barcelona Spain (2008)

Organization Overview

First Clinical Trial

2014

NCT02115139

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2020

Timeline

NOW

Now

Alternative names

Grupo Español Multidisciplinar de Melanoma

Active Ingredients

Drugs in Phase 2 Trials (10)

binimetinib (mektovi) (1 trial)

cediranib (1 trial)

cobimetinib (cotellic) (1 trial)

durvalumab (imfinzi) (1 trial)

encorafenib (braftovi) (1 trial)

ipilimumab (yervoy) (2 trials)

nivolumab (opdivo) (1 trial)

sitravatinib (1 trial)

tislelizumab (1 trial)

vemurafenib (zelboraf) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Brain Neoplasms (Phase 2)

Melanoma (Phase 2)

Neoplasm Metastasis (Phase 2)

Neoplasms, Second Primary (Phase 2)

Uveal Neoplasms (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 6
# of Trial APIs: 10